| Literature DB >> 22405072 |
Kyoichiro Tsuchiya1, Jun Tanaka, Yu Shuiqing, Carrie L Welch, Ronald A DePinho, Ira Tabas, Alan R Tall, Ira J Goldberg, Domenico Accili.
Abstract
Atherosclerotic cardiovascular disease is the leading cause of death in insulin-resistant (type 2) diabetes. Vascular endothelial dysfunction paves the way for atherosclerosis through impaired nitric oxide availability, inflammation, and generation of superoxide. Surprisingly, we show that ablation of the three genes encoding isoforms of transcription factor FoxO in endothelial cells prevents atherosclerosis in low-density lipoprotein receptor knockout mice by reversing these subphenotypes. Paradoxically, the atheroprotective effect of FoxO deletion is associated with a marked decrease of insulin-dependent Akt phosphorylation in endothelial cells, owing to reduced FoxO-dependent expression of the insulin receptor adaptor proteins Irs1 and Irs2. These findings support a model in which FoxO is the shared effector of multiple atherogenic pathways in endothelial cells. FoxO ablation lowers the threshold of Akt activity required for protection from atherosclerosis. The data demonstrate that FoxO inhibition in endothelial cells has the potential to mediate wide-ranging therapeutic benefits for diabetes-associated cardiovascular disease. Copyright ÂEntities:
Mesh:
Substances:
Year: 2012 PMID: 22405072 PMCID: PMC3315846 DOI: 10.1016/j.cmet.2012.01.018
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287